Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q8TEA1

UPID:
NSUN6_HUMAN

ALTERNATIVE NAMES:
NOL1/NOP2/Sun and PUA domain-containing protein 1; NOL1/NOP2/Sun domain family member 6

ALTERNATIVE UPACC:
Q8TEA1; B0YJ54

BACKGROUND:
The enzyme tRNA (cytosine(72)-C(5))-methyltransferase NSUN6, recognized alternatively as NOL1/NOP2/Sun and PUA domain-containing protein 1 or its family member 6, is pivotal in cellular function. It specifically targets the C5 position of cytosine 72 in certain tRNA molecules for methylation. This modification is critical for the stability and efficiency of tRNA, impacting overall protein production and cellular health.

THERAPEUTIC SIGNIFICANCE:
Exploring the function of tRNA (cytosine(72)-C(5))-methyltransferase NSUN6 holds promise for unveiling new therapeutic avenues. Given its integral role in tRNA methylation and protein synthesis, targeting NSUN6 could lead to innovative treatments for diseases at their genetic and molecular roots.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.